ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1575916
SLC2A1 and MPST as diagnostic and prognostic biomarkers of potential endometrial cancer
Provisionally accepted
- 1Second Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China
- 2Hebei Medical University, Shijiazhuang, Hebei Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Uterine corpus endometrial carcinoma (UCEC) is the predominant neoplasm affecting the female reproductive system. Early diagnosis of UCEC is crucial for improving patient survival rates. In this study, we selected and investigated two specific genes associated with hydrogen sulfide(H2S): SLC2A1, which encodes a glucose transporter, and MPST, which encodes 3-mercaptopyruvate thiotransferase.Both SLC2A1 and MPST have been identified as important regulators in cancer. The objective of this study was to investigate the potential significance of SLC2A1 and MPST in terms of UCEC diagnosis and prognosis. Our analysis using Kaplan-Meier survival curves and receiver operating characteristic (ROC) curves demonstrated robust diagnostic and prognostic significance for both SLC2A1 and MPST.Moreover, our research revealed a significant association between the expression levels of SLC2A1 and MPST, immune cell infiltration, immune checkpoint gene presence, and TP53 in UCEC tissues. Furthermore, we observed that DNA methylation status of the CpG island of SLC2A1 and the MPST gene is associated with UCEC prognosis. These findings suggest that SLC2A1 and MPST genes hold promise in distinguishing endometrial cancer patients from normal cases, highlighting their diagnostic and prognostic potential as biomarkers for UCEC. These results offer encouraging prospects for targeted therapies.
Keywords: SLC2A1, MPST, UCEC, clinical outcome, Immune Cell Infiltration, Immune checkpoint
Received: 13 Feb 2025; Accepted: 27 Jun 2025.
Copyright: © 2025 Xi, Gong, Liu, Cui, Xia, Qin and Du. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jiexian Du, Second Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.